
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Thoracic-Lumbar Arthrodesis- Implanet Jazz
Francis Farhadi
Spondylolisthesis
Spinal Stenosis
Degenerative Disease
Establish a data repository of patients who have undergone single, two-, or three-level
lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System. expand
Establish a data repository of patients who have undergone single, two-, or three-level lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System. Type: Observational [Patient Registry] Start Date: Feb 2022 |
|
Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI
Sam Tyagi
Descending Aortic Dissection
Postoperative Pain
Thoracoabdominal Aortic Aneurysm
The objective of this study is to identify the opioid-sparing effects, and pain-reduction
potential of low dose, sub-dissociative ketamine on patients undergoing thoracic
endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion
(NCI). expand
The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI). Type: Interventional Start Date: Dec 2020 |
|
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Nicole Hamblett
Cystic Fibrosis
The REACH study is for people with CF who do not take cystic fibrosis transmembrane
conductance regulator (CFTR) modulators. The goal of the REACH study is to collect
research data, including health data and specimens, from people with CF who do not take
CFTR modulators. This data may be used to in1 expand
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study. Type: Observational Start Date: Sep 2024 |
|
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral1
Craig van Horne, MD, PhD
Parkinson's Disease
The investigators propose a Phase I single surgical-center, double-blinded randomized
parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT)
delivery into the NBM or the alternate target also affecting cognition in this
population, the substantia nigra (SN), to address1 expand
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery. Type: Interventional Start Date: Jul 2025 |
|
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
John Bauer
Obesity and Overweight
Obese Adolescents
Weight Management
Weight Loss
Cardiovascular Disease Risk Factor
The goal of this clinical trial is to learn if the drug semaglutide changes markers of
disease risk as it relates to weight in children ages 12-15 years old who are obese
(class 2 or 3). The main questions it aims to answer are:
- How do the rate of weight loss, body mass index (BMI), body comp1 expand
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: - How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? - How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss? - Are there differences in the above factors between males and females and are there key factors to help improve the outcomes? Participants will be given semaglutide for this study. During the course of the study, participants will: - have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug) - have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured - have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study) - have follow up visits with the study doctor - be asked to take a pregnancy test if they are female and have started menstruation Type: Observational Start Date: Jun 2025 |
|
Improving Behavioral Health for Caregivers and Children After Pediatric Injury
Medical University of South Carolina
Quality of Life
PTSD
Depression Not Otherwise Specified
Child Externalizing Behavior
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000
children experiencing injuries that require hospitalization each year. These children,
and their caregivers, are affected in many ways that may affect quality of life,
emotional and behavioral health, physical reco1 expand
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This proposal builds on prior research from the investigative team to test a technology-assisted, stepped care behavioral health intervention for children (<12 years) and their caregivers after PTI, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), via a hybrid type I effectiveness-implementation trial with 348 families randomly assigned to CAARE (n=174) vs. guideline-adherent enhanced usual care (EUC) (n=174). Type: Interventional Start Date: May 2025 |
|
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
University of Nebraska
Rectal Cancer
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of
investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course
chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal
adenocarcinoma (RAC) patients. expand
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients. Type: Interventional Start Date: Aug 2022 |
|
Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and1
Francis Farhadi
Spinal Cord Stimulation
Electric Stimulation Therapy
Traumatic Spinal Cord Injury
Cervical Myelopathy
The study will be a non-randomized, non-blinded pilot study to analyze the safety and
feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The
aim is to include 30 total patients, 10 patients in each of 3 groups:
1. Non-traumatic spinal cord injury (ntSCI) with d1 expand
The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 total patients, 10 patients in each of 3 groups: 1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention. 2. Early tSCI screened during the hospital admission when cervical/thoracic spinal injury was diagnosed. 3. Delayed tSCI (control) screened 6-24 months after acute cervical/thoracic spinal injury. Type: Interventional Start Date: Oct 2024 |
|
Prospective Evaluation of Pathways for Preterm Birth
John O'Brien, MD
Preterm Birth
Cervix; Pregnancy
This is a single center, prospective cohort study of pregnant patients at high risk for
spontaneous preterm birth: patient's with history of spontaneous preterm birth, patient's
with a short cervix and patient's symptomatic for preterm birth will be included. A
control cohort of nulliparous patient1 expand
This is a single center, prospective cohort study of pregnant patients at high risk for spontaneous preterm birth: patient's with history of spontaneous preterm birth, patient's with a short cervix and patient's symptomatic for preterm birth will be included. A control cohort of nulliparous patients without a short cervix will be recruited to provide baseline data. Plan to enroll 240 patients identified through our ultrasound unit with goal of 60 patients in each group. Type: Observational Start Date: Feb 2022 |
|
PT150 Drug for Use in Alcohol Use Disorder
Pop Test Oncology LLC
Alcohol Use Disorder
The goal of this study is to learn if PT150 can reduce the behavioral and physical
effects of stress, alcohol, and alcohol use in people with alcohol use disorder. expand
The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder. Type: Interventional Start Date: Feb 2025 |
|
Repeated CBD Administration and Cannabis Outcomes
Hannah Harris
Cannabis
Abuse Liability
Experimental Pain in Healthy Human Participants
This outpatient study examines how cannabidiol (CBD) affects the behavioral and
pain-relieving effects of cannabis. expand
This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis. Type: Interventional Start Date: Jun 2026 |
|
Cocaine and Pentoxifylline (BED IN 47)
William Stoops
Cocaine Use Disorder
This will be a human laboratory study evaluating the influence of pentoxifylline
treatment on the effects of cocaine. Supported by and included in the Helping to End
Addiction Long-term® (HEAL) Initiative. expand
This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative. Type: Interventional Start Date: Nov 2025 |
|
WRAP North America
Merit Medical Systems, Inc.
Venous Stenosis
Venous Occlusion
The goal of this observational study is to investigate the safety and efficacy of the
WRAPSODY CIE in a real-world North American population. Participants treated with the
WRAPSODY CIE device in accordance with the device instructions for use will be followed
in accordance with standard of care up1 expand
The goal of this observational study is to investigate the safety and efficacy of the WRAPSODY CIE in a real-world North American population. Participants treated with the WRAPSODY CIE device in accordance with the device instructions for use will be followed in accordance with standard of care up to 3-years post-procedure. Type: Observational Start Date: Jul 2025 |
|
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Pancreatic Ductal Adenocarcinoma
Gastric Cancer
Esophageal Cancer
Colorectal Cancer
Ovarian Cancer
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and
[212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation
Protein (FAP)-positive. expand
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive. Type: Interventional Start Date: Apr 2025 |
|
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
Timothy Mullett
Cancer
Health Care Utilization
The C4 program aims to provide a multi-level intervention program (Patient Level,
Healthcare Team and Healthcare System Level) that improves the coordination of care with
supportive/ancillary care providers and community services through the use of patient
navigation and a digital needs assessment1 expand
The C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services. Type: Interventional Start Date: Feb 2024 |
|
Cannabis and Opioid Use Disorder
Shanna Babalonis, PhD
Opioid Use Disorder
This study plans to enroll participants with opioid use disorder who are not currently
seeking treatment to assess the effects of cannabis on opioid withdrawal and other
related outcomes. expand
This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes. Type: Interventional Start Date: Sep 2024 |
|
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migra1
H. Lundbeck A/S
Migraine
The main goal of the study is to assess the long-term safety of eptinezumab on children
and adolescents ages 6 to 17 with chronic or episodic migraine. expand
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine. Type: Interventional Start Date: Dec 2021 |
|
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconst1
Austin V Stone
ACL Injury
Meniscus Tear
Post-traumatic Osteoarthritis
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month
course of oral montelukast after ACL reconstruction reduces systemic markers of
inflammation and biochemical and imaging biomarkers of cartilage degradation. This study
will specifically target older ACL reconstr1 expand
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery. Type: Interventional Start Date: Feb 2021 |
|
Primary Subtalar Arthrodesis for Calcaneal Fractures
Wake Forest University Health Sciences
Calcaneus Fracture
Management of severe injuries to the heel (displaced intra-articular calcaneus fractures)
continues to be a major challenge for orthopedic surgeons. Previous studies have
demonstrated poor outcomes, and results show that patients experience long-term pain and
decreased quality of life postoperative1 expand
Management of severe injuries to the heel (displaced intra-articular calcaneus fractures) continues to be a major challenge for orthopedic surgeons. Previous studies have demonstrated poor outcomes, and results show that patients experience long-term pain and decreased quality of life postoperatively. Poor outcomes are driven by pain, in particular, which is linked to post-traumatic subtalar arthritis. Type: Interventional Start Date: Sep 2024 |
|
Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life1
Laurie McLouth
Lung Cancer
This study will compare the effects of a brief supportive intervention, called Pathways,
against enhanced usual care on the mental health and quality of life of people undergoing
treatment for advanced lung cancer. Patients will complete baseline survey measures and
be randomized to intervention. S1 expand
This study will compare the effects of a brief supportive intervention, called Pathways, against enhanced usual care on the mental health and quality of life of people undergoing treatment for advanced lung cancer. Patients will complete baseline survey measures and be randomized to intervention. Survey measures will be collected again mid-intervention, post-intervention and at 6- and 12-week follow-up, with analyses focused on changes pre- to post-intervention. Type: Interventional Start Date: Nov 2023 |
|
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Neuroendocrine Tumors Unresectable
Neuroendocrine Tumor Metastatic
Gastroenteropancreatic Neuroendocrine Tumor
Bronchial Neuroendocrine Tumor
Paraganglioma
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted
Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors expand
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors Type: Interventional Start Date: Sep 2023 |
|
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Ken1
University of Arkansas
Hearing Loss
This trial will evaluate a multilevel intervention (STAR model) that combines mobile
health (mHealth) hearing screening tools with telemedicine technology for specialty care
access in rural Kentucky schools. An initial version of the model was used in rural
Alaska where telemedicine-based specialty1 expand
This trial will evaluate a multilevel intervention (STAR model) that combines mobile health (mHealth) hearing screening tools with telemedicine technology for specialty care access in rural Kentucky schools. An initial version of the model was used in rural Alaska where telemedicine-based specialty referral improved both proportion of children receiving follow-up and time to follow-up. The refined STAR model will utilize an enhanced mHealth screening protocol that includes tympanometry for the detection of middle ear disease. The STAR model will also include a specialty telemedicine referral process in schools for children who refer school screening. Type: Interventional Start Date: Sep 2022 |
|
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
Major Extremity Trauma Research Consortium
Post Operative Surgical Site Infection
The proposed study is a multi-center, prospective randomized controlled trial comparing
current standard of care treatment to the SEXTANT treatment protocol in patients with
Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot. expand
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot. Type: Interventional Start Date: May 2021 |
|
Neurocognitive Ankle Training for Instability to Optimize Neuromusculoskeletal Outcomes (NATION)
Womack Army Medical Center
Chronic Ankle Instability
The purpose of this study is to examine the effectiveness of a novel ankle rehabilitation
protocol on improving clinical and health outcomes in physically active individuals with
chronic ankle instability (CAI). Our central hypothesis is NATION, a novel rehabilitation
intervention that includes neu1 expand
The purpose of this study is to examine the effectiveness of a novel ankle rehabilitation protocol on improving clinical and health outcomes in physically active individuals with chronic ankle instability (CAI). Our central hypothesis is NATION, a novel rehabilitation intervention that includes neurocognitive tasks, will improve overall health and function, and reduce lower extremity musculoskeletal injury in physically active individuals with CAI. Type: Interventional Start Date: Oct 2025 |
|
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Prakash Pandalai
Peritoneal Carcinomatosis
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically
been associated with poor overall survival (≤ 12 months) with few treatment options.
Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules,
combined with direct administration of hea1 expand
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options. Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal carcinomatosis. IP chemotherapy allows delivery of a high dose of cytostatic drug directly onto the peritoneal surfaces at risk for microscopic residual disease while systemic exposure remains limited. Additionally, hyperthermia is known to enhance the cytotoxicity of several agents (including Mitomycin C) and improves the depth of peritoneal penetration. This trial will be a randomized phase 2 comparison of flat dose versus weight-based dose Mitomycin C. The hypothesis of this study is that HIPEC weight-based dosing may result in similarly effective peritoneal Mitomycin C concentrations with less systemic absorption and potential systemic toxicity, compared with the HIPEC flat dosing approach in patients undergoing CRS/HIPEC. Type: Interventional Start Date: Jun 2021 |